Preparation and characterization of tetrabenazine enantiomers against vesicular monoamine transporter 2

ACS Medicinal Chemistry Letters

Volumn 1, Issue 3, 2010, Pages 105-109

  Yu, Qian Sheng ^a   Luo, Weiming ^a   Deschamps, Jeffery ^b   Holloway, Harold W ^a   Kopajtic, Theresa ^c   Katz, Jonathan L ^c   Brossi, Arnold ^d   Greig, Nigel H ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b NAVAL RESEARCH LABORATORY   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Huntington's chorea; hyperkinesias; Tetrabenazine enantiomers; vesicular monoamine transporter 2 (VMAT2)

Indexed keywords

TETRABENAZINE; TETRABENAZINE 10 CAMPHORSULFONATE; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ARTICLE; COMPARATIVE STUDY; DRUG SYNTHESIS; ENANTIOMER; INHIBITION KINETICS; NONHUMAN; OPTICAL ROTATION; PRIORITY JOURNAL; RAT; X RAY CRYSTALLOGRAPHY;

EID: 77956639647     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml1000189     Document Type: Article

References (27)

1. Brossi, A.; Lindlar, H.; Walter, M.; Schnider, O. Syntheseversuche in der Emetin Reihe 1. Mitteilung 2-Oxo-hydrobenzo[a]chinolizine. Helv. Chim. Acta 1958, 41, 119 - 139; U.S. 2830993 (1958 to Hoffmann-La Roche).
2. Pletscher, A.; Brossi, A.; Gey, K. F. Benzoquinolizine derivatives: a new class of monoamine decreasing drugs with psychotropic action Int. Rev. Neurobiol. 1962, 4, 275-306
3. Kenney, C.; Jankovic, J. Tetrabenazine in the treatment of hyperkinetic movement disorders Expert Rev. Neurother. 2006, 6, 7-17
4. Fasano, A.; Bentivoglio, A. R. Tetrabenazine Expert Opin. Pharmacother. 2009, 10 (17) 2883-2896
5. Scherman, D.; Jaudon, P.; Henry, J. Characterization of the monoamine carrier of chromaffin granule membrane by binding of [2-3H]dihydrotetrabenazine Proc. Natl. Acad. Sci. U.S.A. 1983, 80, 584-588
6. Thiriot, D. S.; Ruoho, E. A. Mutagenesis and Derivatization of Human Vesicle Monoamine Transporter 2 (VMAT2) Cysteines Identifies Transporter Domains Involved in Tetrabenazine Binding and Substrate Transport J. Biol. Chem. 2001, 276, 27304-27315
7. Mestre, T.; Ferreira, J.; Coelho, M. M.; Rosa, M.; Sampaio, C. Therapeutic interventions for symptomatic treatment in Huntington's disease. Cochrane Database Syst. Rev. 2009, 3, CD006456.
8. Kenney, C.; Hunter, C.; Jankovic, J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders Mov. Disord. 2007, 22, 193-197 (Pubitemid 46374760)
9. Fasano, A.; Cadeddu, F.; Guidubaldi, A.; Piano, C.; Soleti, F.; Zinzi, P.; Bentivoglio, A. R. The long-term effect of tetrabenazine in the management of Huntington disease Clin. Neuropharmacol. 2008, 31, 313-318
10. Rishel, M. J.; Amarasinghe, K. K. D.; Dinn, S. R.; Johnson, B. F. Asymmetric synthesis of tetrabenazine and dihydrotetrabenazine J. Org. Chem. 2009, 74, 4001-4004
11. Openshaw, H. T.; Whittaker, N. The synthesis of emetine and related compounds. Part V. A stereochemically favourable synthesis of emetine J. Chem. Soc. 1963, 1461-1471
12. Openshaw, H. T.; Whittaker, N. The synthesis of emetine and related compounds. Part IV. A new synthesis of 3-substituted 1,2,3,4,6,7-hexahydro-9,10- dimethoxy-2-oxo-11bH-benzo[a]quinolizines J. Chem. Soc. 1963, 1449-1460
13. Murahashi, S.; Naota, T.; Taki, H. Ruthenium-catalysed oxidation of secondary amines to imines using t-butyl hydroperoxide J. Chem. Soc. Chem. Commun. 1985, 613
14. +.
15. Organic Syntheses; Wiley & Sons: New York, 1941; Collect. Vol. I, p 248.
16. +.
17. +.
18. 2-N).
19. +.
20. Takahashi, N.; Miner, L. L.; Sora, I.; Ujike, H.; Revay, R. S.; Kostic, V.; Jackson-Lewis, V.; Prezedborski, S.; Uhl, G. R. VMAT2 knockout mice: Heterozygotes display reduced amphetamine conditioned reward, enhanced amphetamine locomotion and enhanced MPTP toxicity Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 9938-9943
21. Riddle, E. L.; Fleckenstein, A. E.; Hanson, G. R. Role of monoamine transporters in mediating psychostimulant effects AAPS J. 2005, 7, E847-E851
22. Zheng, G.; Dwoskin, L. P.; Crooks, P. A. Vesicular monoamine transporter 2: Role as a novel target for drug development AAPS J. 2006, 8, E682-E692
23. Nickell, J. R.; Krishnamurthy, S.; Norrholm, S.; Deaciuc, G.; Siripurapu, K. B.; Zheng, G.; Crooks, P. A.; Dwoskin, L. P. Lobelane Inhibits Methamphetamine-Evoked Dopamine Release via Inhibition of the Vesicular Monoamine Transporter-2 J. Pharmacol. Exp. Ther. 2010, 332, 612-621
24. Mehvar, R.; Jamali, F.; Watson, M. W.; Skelton, D. Pharmacokinetics of tetrabenazine and its major metabolite in man and rat. Bioavailability and dose dependency studies Drug Metab. Dispos. 1987, 15, 250-255
25. Roberts, M. S.; McLean, S.; Millingen, K. S.; Galloway, H. M. The Pharmacokinetics of tetrabenazine and its hydroxy metabolite in patients treated for involuntary movement disorders Eur. J. Clin. Pharmacol. 1986, 29, 703-708
26. Kilbourn, M. R.; Lee, L.; Vander Borght, T.; Jewett, D.; Frey, K. Binding of alpha-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific Eur. J. Pharmacol. 1995, 278, 249-252
27. Kilbourn, M. R.; Lee, L.; Jewett, D. M.; Vander Borght, T.; Koeppe, R. A.; Frey, K. A. In vitro and in vivo binding of -dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific J. Cereb. Blood Flow Metab. 1995, 15, S650